ASCO 2024 Top 3 Practice Changing Head & Neck Cancer Studies

Editor

2 months ago

Dr. Shlomo Koyfman, MD, discussing practice-changing head and neck cancer studies at ASCO 2024.

ASCO 2024 Top 3 Practice Changing Head & Neck Cancer Studies

Introduction

ASCO 2024 Head & Neck Cancer developments brought forth several groundbreaking studies in the field of head and neck cancer, showcasing advancements that could potentially change clinical practices. Dr. Shlomo Koyfman, MD, highlighted three pivotal studies that stood out during the conference. These studies delve into proton therapy, biomarker trials, and the role of immunotherapy, offering new insights and potential changes in treatment approaches for head and neck cancer patients.

1. IMRT vs. IMPT Proton Therapy Study

The much-anticipated IMRT (Intensity-Modulated Radiation Therapy) versus IMPT (Intensity-Modulated Proton Therapy) phase three study finally provided data after a decade of research. The results confirmed that proton therapy is just as effective as IMRT in treating head and neck cancer, with no compromises on cure rates. A significant advantage of proton therapy is its precision, which reduces the risk of side effects. Notably, the study found that patients undergoing proton therapy had a significantly lower incidence of requiring feeding tubes. Even when feeding tubes were necessary, the duration of use was much shorter compared to those receiving IMRT. This finding marks a substantial win for proton therapy, making it a more favorable option for managing head and neck cancer with fewer side effects.

2. Nancy Lee’s Biomarker Trial at Sloan Kettering

Dr. Nancy Lee’s group at Sloan Kettering introduced an innovative biomarker trial using F MISO, a hypoxia imaging technique via PET scan. This method identifies tumors with low oxygen levels, which are typically more resistant to treatment. The study revealed that most tumors, despite appearing large and aggressive on conventional scans, did not show significant hypoxia. For those without hypoxia, patients had excellent outcomes. Remarkably, these patients received a shortened course of chemoradiation, stopping after just three weeks if scans looked favorable, instead of the standard seven weeks. This reduction in treatment duration resulted in fewer side effects, lower costs, and still maintained high cure rates. However, the limitation lies in the non-availability of F MISO PET scans outside of research settings. Nonetheless, a forthcoming phase three study aims to validate these findings and potentially revolutionize treatment protocols for HPV-positive head and neck cancer patients.

3. The Pathway Study on Immunotherapy

The Pathway study attempted to evaluate the efficacy of adjuvant immunotherapy in head and neck cancer patients post-curative treatment. While previous trials like Javelin 100 and KEYNOTE-412 were disappointing, this study provided some promising results, albeit with limitations. The study involved a small cohort of high-risk patients, showing a progression-free survival benefit but no significant overall survival improvement. Although the study’s scale and diverse patient groups may limit its impact on changing current practices, it suggests that more targeted approaches could potentially benefit specific patient cohorts, particularly those with high PD-L1 expression. Future studies with more precise patient selection could unveil the true potential of immunotherapy in this setting.

Conclusion

ASCO 2024 presented compelling data that could reshape the landscape of head and neck cancer treatment. The IMPT study reinforced the efficacy and safety of proton therapy, Nancy Lee’s biomarker trial hinted at personalized treatment pathways, and the Pathway study highlighted the ongoing exploration of immunotherapy’s role. These studies underscore the importance of continued research and innovation in oncology, paving the way for more effective and less toxic treatment options.